Royalty Pharma plc Class ARPRX
Close of Friday, October 23, 2026 · Royalty Pharma plc Class A is trading above its Pivot, OnlyAlpha's long-term trend line.
Price
$63.85
vs its Pivot
+21.4%
OnlyAlpha Score
78
Trend
Above its Pivot
Last 12 months. Solid line: price. Dashed green: the Pivot. ▲ closed at least 1% above the Pivot (in) · ▼ closed below it (out). Hover or drag across the chart for any day.
Returns
| 1 month | Year to date | 1 year | 3 years / yr | 5 years / yr |
|---|---|---|---|---|
| +9.5% | +67.5% | +76.7% | +35.9% | +13.3% |
Dividend: $0.93 a share over the last 12 months, a 1.45% yield at today's price.
Who runs and owns it
Run by Pablo Legorreta (founder, CEO), one of the Forbes billionaires.
In these funds
IHE · 4.41%IYH · 0.38%DGRO · 0.07%IYY · 0.04%
Members of Congress who traded it
| Ro Khanna D · CA | 1 buys · 1 sells · last sell 2026-01-23 |
Suppliers, customers and partners
RPRX sells to
| Vertex Pharmaceuticals | CF franchise, $917M 2025 royalty receipts |
| Biogen | Tysabri, $250M |
| Johnson & Johnson (Janssen) | Tremfya, $178M |
| AbbVie | Imbruvica, $170M (with J&J) |
| Novartis | Promacta, $142M |
| Gilead Sciences | Trodelvy, $47M |
Partners and deals
| Biogen | 2025 funding agreement |
| Arrowhead Pharmaceuticals | bought olpasiran royalties |
From the companies' own annual reports filed with the SEC.
Healthcare · Biotech
Get RPRX in your free daily emailAfter every close: whether RPRX is above or below its Pivot, its OnlyAlpha Score, and any new buy or sell signal, along with the rest of your list.
Track RPRX free → Full Stock check
Track RPRX free → Full Stock check